A Phase I Study of Humanized 3F8 Monoclonal Antibody in Patients with High-Risk Neuroblastoma and GD2-Positive Tumors
[Protocol 11-009] |
Basu, Ellen, MD, PhD |
A Phase I Study of Dasatinib and Ipilimumab for Patients with Advanced GIST or Other Sarcomas
[Protocol 12-083] |
Carvajal, Richard, MD |
A Phase II Study of Trebananib (AMG 386) for the Treatment of Inoperable Advanced Angiosarcoma
[Protocol 12-128] |
D'Angelo, Sandra, MD |
A Phase II Study of PD0332991 in Patients with Advanced or Metastatic Liposarcoma
[Protocol 10-094] |
Dickson, Mark, MD |
A Phase II Study of MLN8237 in Advanced or Metastatic Sarcoma
[Protocol 12-194] |
Dickson, Mark, MD |
A Phase 1B/II Study of GDC-0449 Plus RO4929097 in Advanced/Metastatic Sarcomas
[Protocol 10-049] |
Gounder, Mrinal, MD |
A Phase III Study of Gemcitabine, Docetaxel, and Doxorubicin versus Observation in Women with High-Grade Uterine Leiomyosarcoma
[Protocol 12-177] |
Hensley, Martee, MD |
A Phase III Study of Paclitaxel plus Carboplatin Versus Ifosfamide plus Paclitaxel in Chemotherapy-Naive Patients with Newly Diagnosed Persistent or Recurrent Carcinosarcoma of the Uterus
[Protocol 10-007] |
Hensley, Martee, MD |
A Phase III Study of Trabectedin or Dacarbazine for Previously Treated Advanced Liposarcoma or Leiomyosarcoma
[Protocol 11-143] |
Hensley, Martee, MD |
A Phase II Study of MLN8237 in Patients with Recurrent or Persistent Uterine Leiomyosarcoma
[Protocol 12-164] |
Hyman, David, MD |
A Phase II Study of Sunitinib or Cediranib for Inoperable Metastatic Alveolar Soft Part Sarcoma
[Protocol 12-095] |
Keohan, Mary, MD |
A Pilot Trial of Irinotecan, Temozolomide, and Bevacizumab plus High-Dose Chemotherapy for Newly Diagnosed Patients with Desmoplastic Small Round Cell Tumor
[Protocol 10-091] |
Magnan, Heather, MD |
A Phase I Study of Humanized 3F8 plus Interleukin-2 in Patients with High-Risk Neuroblastoma and GD2-Positive Tumors
[Protocol 12-116] |
Roberts, Stephen, MD |
A Phase Ib/II Study of Gemcitabine and Docetaxel Plus Pazopanib for the Neoadjuvant (Presurgical) Treatment of Soft-Tissue Sarcoma
[Protocol 11-104] |
Tap, William, MD |
A Phase I Study of PLX3397 in Patients with Advanced Solid Tumors
[Protocol 12-156] |
Tap, William, MD |
A Phase IB/II Study Evaluating Doxorubicin with or without a IMC-3G3 to Treat Advanced Soft-Tissue Sarcoma
[Protocol 10-156] |
Tap, William, MD |
A Phase III Study of Doxorubicin Alone or in Combination with TH-302 in Patients with Locally Advanced Inoperable or Metastatic Soft-Tissue Sarcoma
[Protocol 11-203] |
Tap, William, MD |
A Phase II Study of Cyclophosphamide, Topotecan, and Bevacizumab in Patients with Relapsed or Refractory Ewing's Sarcoma and Neuroblastoma
[Protocol 11-183] |
Trippett, Tanya, MD |
A Phase II Study of Cixutumumab plus Temsirolimus in Children with Recurrent or Refractory Sarcoma
[Protocol 12-188] |
Wexler, Leonard, MD |
A Phase II Trial of Vinorelbine and Cyclophosphamide with Bevacizumab or Temsirolimus in Patients with Recurrent/Refractory Rhabdomyosarcoma
[Protocol 11-026] |
Wexler, Leonard, MD |
